Psoriasis Trial, Recruiting NCT05994976 Sponsor: Innovaderm Research Inc. Condition: Psoriasis
Back to Psoriasis

Psoriasis Trial, Recruiting

NCT05994976
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

All participants:

  • People who are willing to take part and are able to give their informed agreement before any study procedures begin.
  • People who are willing to follow all study procedures and are available for the full duration of the study.

Healthy volunteers:

  • People aged 18 or older who are in good general health, as judged by the study doctor.

People with Acne:

  • People aged 18 to 45 years old with acne.

People with Atopic Dermatitis (AD):

  • People aged 18 or older who have a confirmed diagnosis of active atopic dermatitis (a type of eczema), assessed using a standard set of diagnostic criteria.

People with Chronic Hand Eczema (CHE):

  • People aged 18 or older who have had chronic hand eczema for at least 6 months before the screening visit.

People with Hidradenitis Suppurativa (HS):

  • People aged 18 or older who have a confirmed diagnosis of active hidradenitis suppurativa (a long-term skin condition causing painful lumps) lasting at least 6 months before screening.

People with Palmoplantar Pustulosis (PPP):

  • People aged 18 or older who have had at least a 6-month history of pustules (small pus-filled spots) on the palms and/or soles of the feet, without signs of infection.

People with Psoriasis:

  • People aged 18 or older with psoriasis.

Who may not be able to join:

  • Women who are pregnant or planning to become pregnant during the study.
  • People who have a skin disease or skin condition that, in the study doctor's opinion, would interfere with how results are assessed.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 22 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Robert Bissonnette, MD, Innovaderm Research Inc.

Phone: 514-521-4285

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Innovaderm Research Inc.
Registry
ClinicalTrials.gov
Start date
17 October 2023
Est. completion
1 August 2028

Where this trial is recruiting

🇨🇦 Canada

Primary endpoints

Untargeted biomarker approach with gene expression profile of skin samples; Exploratory biomarker and gene expression analyses.

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 22 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov